How fast does oral dexamethasone work in mild to moderately severe croup? A randomized double-blinded clinical trial

Milana Dobrovoljac1, Gary C Geelhoed

  • 1Emergency Department, Princess Margaret Hospital for Children, Perth, Western Australia, Australia.

Insights

A lower dose of dexamethasone (0.15 mg/kg) provides rapid relief for children with croup, showing significant benefits within 30 minutes. This finding challenges previous recommendations for delayed treatment onset.

Area of Science:

  • Pediatric Emergency Medicine
  • Pharmacology
  • Clinical Trials

Background:

  • Controversy exists regarding optimal dexamethasone dosage and onset of action for pediatric croup.
  • Previous reviews suggested higher doses (0.6 mg/kg) with expected benefit after 4-6 hours.

Purpose of the Study:

  • To evaluate the efficacy of a lower dose (0.15 mg/kg) of oral dexamethasone in treating pediatric croup.
  • To determine if this lower dose provides therapeutic benefit within 30 minutes.

Main Methods:

  • A randomized, double-blinded clinical trial involving children aged over 6 months with mild to moderate croup (Westley score 1-6).
  • Participants received either 0.15 mg/kg dexamethasone or placebo.
  • Croup scores and vital signs were monitored every 10 minutes for up to 1 hour.

Main Results:

  • A statistically significant reduction in croup scores was observed in the dexamethasone group by 30 minutes post-administration.
  • A trend towards lower croup scores was evident from 10 minutes in the dexamethasone group.
  • Baseline characteristics were comparable between groups, except for a higher respiratory rate in the placebo group.

Conclusions:

  • Oral dexamethasone at 0.15 mg/kg offers rapid therapeutic benefit for pediatric croup, with effects seen by 30 minutes.
  • This early onset of action contrasts with the previously suggested 4-hour timeframe.
  • The findings may support earlier and broader treatment of croup, potentially reducing parental and physician concerns about delayed benefits.
Abstract

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Dosage Regimen: Multiple Oral Dosage01:25

Dosage Regimen: Multiple Oral Dosage

Understanding how a drug's concentration fluctuates within the body over time is crucial in pharmacokinetics, particularly with multiple oral doses. A graphical representation of multiple oral dosages provides insight into these dynamics. Typical accumulation curves of a drug's concentration in the body reveal a sawtooth pattern, indicating periodic peaks and troughs correlating with each dose administration and the drug's subsequent elimination.The plasma concentration at any time during an...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...